Author: RePair Admin

We’re pleased to be named as one of the TechAlliance-supported companies in Cohort 3 of i.d.e.a. Fund! This program is funded by the Government…

In June 2024, we competed in the Hult Prize Semifinals in Mexico. After the preliminary round, Re:Pair Genomics was selected as one of the…

On June 13, 2024, Re:Pair Genomics was invited to present and feature our venture in the Biotech Expo Stage, organized by MaRS Impact Health…

Building a BioTech Venture, otherwise known as BBTV,  is a program offered at the University of Toronto (UofT), by Medicine by Design. Medicine by…

On 21st February 2024, our team embarked on an extraordinary journey to participate in the prestigious Hult Prize competition, a global platform known for…

Our team had an incredible day at ConferenceX, held in the MaRS Discovery District! 🚀 The event was truly inspiring, filled with stories from…

On September 7, California Life Sciences and Johnson & Johnson Innovation co-hosted a West Coast Symposium focusing on Cell and Gene Therapy – Advancing…

Impairment of GABAergic inhibitory neuronal function is linked to epilepsy and other neurological and psychiatric disorders. Recombinant adeno-associated virus (rAAV)-based gene therapy targeting GABAergic…

On Wednesday November 9th, 2022, H2i welcomed founders, students, faculty, mentors and more to Pitch Perfect 2022! Marking H2i’s first in-person event since early…

Over 90% of gene therapy clinical trials fail at the moment. The reasons for failure include adverse effects and low efficacy of the treatment.…